Thiazide diuretics alone or with beta-blockers impair glucose metabolism in hypertensive patients with abdominal obesity.
作者信息
Manrique Camila, Johnson Megan, Sowers James R
出版信息
Hypertension. 2010 Jan;55(1):15-7. doi: 10.1161/HYPERTENSIONAHA.109.142620. Epub 2009 Nov 16.
Abstract
摘要
相似文献
1
Thiazide diuretics alone or with beta-blockers impair glucose metabolism in hypertensive patients with abdominal obesity.噻嗪类利尿剂单独使用或与β受体阻滞剂联用会损害腹型肥胖高血压患者的糖代谢。
Hypertension. 2010 Jan;55(1):15-7. doi: 10.1161/HYPERTENSIONAHA.109.142620. Epub 2009 Nov 16.
2
Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications.腹型肥胖对与降压药物相关的不良代谢影响发生率的影响。
Hypertension. 2010 Jan;55(1):61-8. doi: 10.1161/HYPERTENSIONAHA.109.139592. Epub 2009 Nov 16.
3
Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazide.阿替洛尔或氢氯噻嗪短期治疗后高血压参与者血糖变化的预测因素。
Pharmacotherapy. 2014 Nov;34(11):1132-40. doi: 10.1002/phar.1483. Epub 2014 Sep 9.
4
Changes in selected metabolic parameters in patients over 65 receiving hydrochlorothiazide plus amiloride, atenolol or placebo in the MRC elderly trial.在医学研究委员会（MRC）老年人试验中，65岁以上接受氢氯噻嗪加阿米洛利、阿替洛尔或安慰剂治疗的患者选定代谢参数的变化。
BMC Cardiovasc Disord. 2016 Oct 4;16(1):188. doi: 10.1186/s12872-016-0368-2.
5
Genetic Variants Associated With Uncontrolled Blood Pressure on Thiazide Diuretic/β-Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil-SR Trandolapril Study) Trials.噻嗪类利尿剂/β-受体阻滞剂联合治疗时与血压控制不佳相关的遗传变异：PEAR（抗高血压反应的药物基因组学评估）和 INVEST（国际维拉帕米-SR trandolapril 研究）试验。
J Am Heart Assoc. 2017 Nov 2;6(11):e006522. doi: 10.1161/JAHA.117.006522.
6
Comparison of the combination of enalapril and a very low dose of hydrochlorothiazide with atenolol in patients with mild-to-moderate hypertension. Scandinavian Study Group.依那普利与极低剂量氢氯噻嗪联合用药与阿替洛尔治疗轻至中度高血压患者的比较。斯堪的纳维亚研究小组。
Am J Hypertens. 1997 Aug;10(8):899-904. doi: 10.1016/s0895-7061(97)00110-6.
7
Combination therapy with saluretics and atenolol in essential hypertension. Effects on blood pressure, electrolytes and uric acid.
Acta Med Scand Suppl. 1979;625:86-91. doi: 10.1111/j.0954-6820.1979.tb00748.x.
8
Safety and antihypertensive efficacy of carvedilol and atenolol alone and in combination with hydrochlorothiazide.卡维地洛与阿替洛尔单用及与氢氯噻嗪联用的安全性和降压疗效。
Eur J Clin Pharmacol. 1990;38 Suppl 2:S143-6. doi: 10.1007/BF01409485.
9
Antihypertensive and metabolic effects of Angiotensin receptor blocker/diuretic combination therapy in obese, hypertensive African American and white patients.血管紧张素受体阻滞剂/利尿剂联合治疗在肥胖、高血压的非裔美国人和白人患者中的降压和代谢作用。
Am J Ther. 2013 Jan;20(1):2-12. doi: 10.1097/MJT.0b013e318230ae66.
10
PROX1 gene variant is associated with fasting glucose change after antihypertensive treatment.PROX1基因变异与降压治疗后的空腹血糖变化有关。
Pharmacotherapy. 2014 Feb;34(2):123-30. doi: 10.1002/phar.1355. Epub 2013 Oct 9.
引用本文的文献
1
Impact of Angiotensin-Converting Enzyme Inhibitor on Coronary Artery Calcification Evaluated by Intravascular Ultrasound: A Retrospective Cohort Study.血管内超声评估血管紧张素转换酶抑制剂对冠状动脉钙化的影响：一项回顾性队列研究
Health Sci Rep. 2025 Jun 11;8(6):e70900. doi: 10.1002/hsr2.70900. eCollection 2025 Jun.
2
Diuretics: a review of the pharmacology and effects on glucose homeostasis.利尿剂：药理学及其对葡萄糖稳态影响的综述
Front Pharmacol. 2025 Mar 28;16:1513125. doi: 10.3389/fphar.2025.1513125. eCollection 2025.
3
Treatment options for heart failure in individuals with overweight or obesity: a review.超重或肥胖个体心力衰竭的治疗选择：一项综述
Future Cardiol. 2025 Apr;21(5):315-329. doi: 10.1080/14796678.2025.2479378. Epub 2025 Mar 18.
4
Different effects of medications for hypertension on renal function between patients with and without diabetes mellitus undergoing percutaneous coronary intervention: a retrospective single-center cohort study.经皮冠状动脉介入治疗的糖尿病和非糖尿病患者中降压药物对肾功能影响的差异：一项回顾性单中心队列研究。
BMC Cardiovasc Disord. 2023 Oct 14;23(1):509. doi: 10.1186/s12872-023-03547-7.
5
Jacq. Exhibits Antiobesity Properties and Potentially Induces Browning of White Adipose Tissue.雅克氏表现出抗肥胖特性，并可能诱导白色脂肪组织褐变。
Evid Based Complement Alternat Med. 2020 Dec 23;2020:9358563. doi: 10.1155/2020/9358563. eCollection 2020.
6
Drug-induced diabetes type 2: In silico study involving class B GPCRs.药物性 2 型糖尿病：涉及 B 类 GPCR 的计算研究。
PLoS One. 2019 Jan 16;14(1):e0208892. doi: 10.1371/journal.pone.0208892. eCollection 2019.
7
Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial.氨氯吡咪与氨氯吡咪加氢氯噻嗪对比氢氯噻嗪对葡萄糖耐量和血压的影响（PATHWAY-3）：一项平行分组、双盲、随机 4 期临床试验。
Lancet Diabetes Endocrinol. 2016 Feb;4(2):136-47. doi: 10.1016/S2213-8587(15)00377-0. Epub 2015 Oct 18.
8
Gene expression in thiazide diuretic or statin users in relation to incident type 2 diabetes.噻嗪类利尿剂或他汀类药物使用者的基因表达与2型糖尿病发病的关系。
Int J Mol Epidemiol Genet. 2014 Feb 17;5(1):22-30. eCollection 2014.
9
Type 2 diabetes mellitus and hypertension: an update.2型糖尿病与高血压：最新进展
Endocrinol Metab Clin North Am. 2014 Mar;43(1):103-22. doi: 10.1016/j.ecl.2013.09.005. Epub 2013 Dec 12.
10
The effects of antihypertensive drugs on chromium status, glucose metabolism, and antioxidant and inflammatory indices in spontaneously hypertensive rats.抗高血压药物对自发性高血压大鼠铬状态、糖代谢以及抗氧化和炎症指标的影响。
Biol Trace Elem Res. 2014 Jan;157(1):60-6. doi: 10.1007/s12011-013-9864-8. Epub 2013 Nov 19.
本文引用的文献
1
Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications.腹型肥胖对与降压药物相关的不良代谢影响发生率的影响。
Hypertension. 2010 Jan;55(1):61-8. doi: 10.1161/HYPERTENSIONAHA.109.139592. Epub 2009 Nov 16.
2
Realities of newer beta-blockers for the management of hypertension.新型β受体阻滞剂用于高血压管理的现状
J Clin Hypertens (Greenwich). 2009 Jul;11(7):369-75. doi: 10.1111/j.1751-7176.2009.00140.x.
3
Hydrochlorothiazide, but not Candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of Candesartan (MEDICA) Study.氢氯噻嗪而非坎地沙坦会加重胰岛素抵抗并导致内脏和肝脏脂肪堆积：坎地沙坦预防糖尿病作用机制（MEDICA）研究
Hypertension. 2008 Dec;52(6):1030-7. doi: 10.1161/HYPERTENSIONAHA.108.119404. Epub 2008 Nov 3.
4
Metabolic syndrome and incident diabetes: current state of the evidence.代谢综合征与新发糖尿病：证据现状
Diabetes Care. 2008 Sep;31(9):1898-904. doi: 10.2337/dc08-0423. Epub 2008 Jun 30.
5
Risk factor assessment for new onset diabetes: literature review.
Diabetes Obes Metab. 2009 Mar;11(3):177-87. doi: 10.1111/j.1463-1326.2008.00925.x. Epub 2008 Jun 16.
6
Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up.治疗的高血压患者中糖尿病很常见，且心血管风险高：28年随访结果
J Hypertens. 2007 Jun;25(6):1311-7. doi: 10.1097/HJH.0b013e328122dd58.
7
Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis.抗高血压药物临床试验中的新发糖尿病：一项网状Meta分析。
Lancet. 2007 Jan 20;369(9557):201-7. doi: 10.1016/S0140-6736(07)60108-1.
8
Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).随机接受3种不同类别降压治疗的老年非糖尿病成年人的空腹血糖水平与新发糖尿病：抗高血压和降脂治疗预防心脏病发作试验（ALLHAT）的报告
Arch Intern Med. 2006 Nov 13;166(20):2191-201. doi: 10.1001/archinte.166.20.2191.
9
Effect of antihypertensive agents on the development of type 2 diabetes mellitus.抗高血压药物对2型糖尿病发生发展的影响。
Mayo Clin Proc. 2006 Jun;81(6):796-806. doi: 10.4065/81.6.796.
10
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.卡维地洛与美托洛尔对2型糖尿病合并高血压患者的代谢影响：一项随机对照试验
JAMA. 2004 Nov 10;292(18):2227-36. doi: 10.1001/jama.292.18.2227.
Zotero 插件